Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.3%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares fell 5.3% during trading on Monday . The company traded as low as $27.12 and last traded at $27.43. 42,460 shares traded hands during trading, a decline of 77% from the average session volume of 185,633 shares. The stock had previously closed at $28.96.

Analyst Ratings Changes

A number of brokerages have commented on DNTH. Wedbush cut their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Robert W. Baird began coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They set an “outperform” rating and a $58.00 price target for the company. Cantor Fitzgerald began coverage on shares of Dianthus Therapeutics in a research note on Thursday, June 27th. They set an “overweight” rating for the company. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, August 12th. Finally, Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $44.71.

Dianthus Therapeutics Stock Up 0.0 %

The firm has a market cap of $763.07 million, a price-to-earnings ratio of -4.46 and a beta of 1.85. The business’s fifty day moving average is $28.07 and its two-hundred day moving average is $26.11.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The company had revenue of $1.86 million during the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. Research analysts forecast that Dianthus Therapeutics, Inc. will post -2.32 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of DNTH. Bain Capital Life Sciences Investors LLC acquired a new stake in Dianthus Therapeutics during the 1st quarter worth $89,761,000. RA Capital Management L.P. acquired a new stake in Dianthus Therapeutics during the 1st quarter worth $69,990,000. Great Point Partners LLC grew its holdings in Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after acquiring an additional 132,929 shares during the period. Octagon Capital Advisors LP grew its holdings in Dianthus Therapeutics by 15.4% during the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after acquiring an additional 74,000 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after acquiring an additional 384,182 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.